Redx Pharma has quickly established itself as one of the largest biotechnology companies in Europe, focused on the development of a wide range of early stage, proprietary small molecule therapeutics to address high unmet medical needs in cancer and infectious disease.

Find out more


Latest News

Pierre Fabre M├ędicament logo Redx Pharma and Pierre Fabre collaborate in the promising field of Onco-Dermatology
6 March 2014

Redx Pharma and Pierre Fabre Laboratories have today completed a collaboration and option agreement in cancer research.

The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.

The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray described the deal as a highly significant milestone in the company's development.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

 166 employees already

Updated 14/04/14

We Sponsored

A major one day conference looking at the critical issues relating to the development of new anti-infectives and the problem of drug resistance.

BioInfect 2013

Alderley Park Conference Centre, 26/11/13


Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details

Finding new intellectual property that supports development of novel agrochemicals with shorter, less costly development cycles.

View details